Immunitybio Inc.

01/18/2022 | Press release | Distributed by Public on 01/18/2022 17:16

ImmunityBio Announces Results of Phase 2 Metastatic Pancreatic Cancer Trial at ASCO GI with Median Overall Survival of 6.3 Months in Patients with Third-Line Disease, More than[...]